M
Marietta Dermatology Clinical Research | Marietta, GA
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
LY3041658
Finasteride
ABBV-157
CLS006
Secukinumab
Lebrikizumab
Ritlecitinib
RPT193
Clobetasol Propionate
Guselkumab
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 15 total trials
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...
Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib
Locations recently updated
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab
Trial sponsors
D
E
P
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems